NEC Corporation, a Japanese multinational provider of information technology services and products, acquired OncoImmunity, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer. Financial terms were not disclosed. “NEC strongly believes that healthcare based on genomics paves the way for individualized medicine. OncoImmunity is a recognized player in the neoantigen prediction field, and their compelling systems are expected to form valuable synergies with NEC. We are confident that this acceleration of development will provide promising new avenues that lead to better cancer treatments,” said Osamu Fujikawa, Senior Vice President, NEC Corporation.